# GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma

Source: https://onco.cc/trials/nct07209813/  
OnCo record `nct07209813` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of GKL-006 Injection in hepatocellular carcinoma, run by Beijing Gene Key Life Technology Co., Ltd, now recruiting.

## Summary

GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma is a phase 2 interventional study registered as NCT07209813 by Beijing Gene Key Life Technology Co., Ltd, with 48 participants planned, started 2025-11-14 and due to reach its primary completion in 2027-09-30. Interventions recorded: GKL-006 Injection and TACE.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07209813
- Phase: 2
- Setting: A Multicenter, Randomized, Open-Label, Controlled Phase 2 Study of GKL-006 Injection in Combination With Transarterial Chemoembolization (TACE) Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
- Sponsor: Beijing Gene Key Life Technology Co., Ltd
- Enrolled: 48

## Sources

- ClinicalTrials.gov NCT07209813: https://clinicaltrials.gov/study/NCT07209813

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- companies: [Beijing Gene Key Life Technology](https://onco.cc/companies/beijing-gene-key-life-technology/)

---
JSON: https://onco.cc/api/v1/entities/nct07209813.json